Investor Relations
Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
![Woman throwing punch at punching bag.](/image/iStock-10189906601.jpg)
Investor Relations
Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Financial and Operational Metrics
(As of December 31, 2023)
-
$167M
FY’23 Revenue
7% YtY growth
-
$25-30M
Adj. EBITDA expected in 2024
>75%
Adj. EBITDA
growth YtY -
$73M
Cash balance
with no debt
-
#1
OA Pain
U.S. Market Share
~25M
Injections
Worldwide
2024 Annual Meeting Materials
Current Investor Presentation
Latest Quarterly Results
Q1 2024 Earnings
Investor Contacts
Primary IR Contact
-
Mark Namaroff
Vice President, Investor Relations, ESG, and Corporate Communications
Anika Therapeutics, Inc.
Phone: (781) 457-9287
Email: investorrelations@anika.com
-
Transfer Agent
Equiniti Trust Company LLC
6201 15th Avenue
Brooklyn NY 11219
Phone: (800) 967-5449
Want Alerts? Sign up for alerts and never miss an Investor update!